Abstract
Immunotherapy with interleukin 2 and lymphokine-activated killer cells can result in regression of metastatic cancer. Dermatologic complications associated with this therapy include erythema, pruritus, and a mild desquamation. Three patients with a history of psoriasis received high-dose interleukin 2 alone or in conjunction with lymphokine-activated killer cells for treatment of metastatic renal cell carcinoma. Two patients developed an erythrodermic exacerbation during therapy while the third patient experienced a localized flare. Topical treatment was effective in inducing remission in all three patients. Histologic analysis of serial skin biopsy specimens revealed psoriasiform changes in involved skin as well as epidermal spongiosis and a perivascular mononuclear cell infiltrate. The psoriatic exacerbation from interleukin 2 did not affect antitumor response to the therapy and should not be considered a contraindication to treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
